Comparison of JIA response variables in patients receiving etanercept or infliximab during the 12 month open clinical study
| Baseline | Changes from baseline to month 12* | ||||
|---|---|---|---|---|---|
| Characteristics | Etanercept (n=10) Median (IQR) | Infliximab (n=14) Median (IQR) | Etanercept (n=10) Median (95% CI) | Infliximab (n=14) Median (95% CI) | p Value† |
| *Hodges-Lehmann estimate with exact confidence interval; †permutation test with Monte-Carlo estimates of p value between groups. | |||||
| ESR (mm/1st h) | 39 (25–55) | 43 (24–54) | −28.5 (−51.5 to −15.0) | −25.0 (−36.0 to −15.0) | 0.37 |
| Number of swollen joints | 5 (4–17) | 12 (4–18) | −7.5 (−15.0 to −2.0) | −9.0 (−15.0 to −3.5) | 0.71 |
| Number of active joints | 10 (5–19) | 13 (6–21) | −9.5 (−19.0 to −3) | −11.5 (−17.0 to −7.5) | 0.74 |
| Patient’s overall assessment | 36 (18–55) | 36 (23–71) | −24.5 (−50.5 to −7.0) | −27.5 (−47.5 to −12.0) | 0.81 |
| Doctor’s overall assessment | 35 (29–60) | 52 (41–74) | −29.0 (−52.0 to −14.5) | −35.0 (−50.5 to −23.5) | 0.65 |
| CHAQ | 1.19 (0.60–2.03) | 0.88 (0.37–1.63) | −0.81 (−1.44 to −0.19) | −0.31 (−0.75 to −0.25) | 0.12 |